Seeking Alpha

Intercept Pharmaceuticals (ICPT) sells 5M shares at $15 each, the top end of the expected price...

Intercept Pharmaceuticals (ICPT) sells 5M shares at $15 each, the top end of the expected price range, in its Nasdaq IPO. The biotech will receive net proceeds of $68.3M, which it will use to develop its obeticholic acid treatment for a rare autoimmune liver disease called primary biliary cirrhosis. The drug has orphan status in the U.S. and Europe, and is in Phase III trials.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|